Screener / SEC EDGAR /CIK 0001756262 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

TransMedics Group, Inc. TMDX

Compare with peers Embed
FY2025 at a glance

Sales up 37.1%, free cash flow up to $133.6M

XBRL, from each 10-K
RevenueStatements
$605.5M from $441.5M in FY2024
FY2018FY2025
Net incomeStatements
$190.3M from $35.5M in FY2024
FY2018FY2025
Free cash flowStatements
$133.6M from -$80.9M in FY2024
FY2018FY2025
EPS (diluted)Statements
$4.87 from $1.01 in FY2024
FY2018FY2025
Operating marginStatements
17.9% from 8.5% in FY2024
FY2018FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
3.67
Sales (ttm)
727.6M
Net income (ttm)
144.5M
Sales growth
+37.1%
EPS growth
+382%
Sales Q/Q
+41.1%
Free cash flow
44.7M
Gross margin
58.6%
Oper. margin
11.9%
Net margin
19.9%
FCF margin
6.1%
ROA
9.5%
R&D / sales
11.4%
Dividend
0.00
Debt/Eq
-
Curr. ratio
4.53
Cash
511.4M
Op. cash flow (ttm)
112.4M
EBITDA
135.8M
EBITDA margin
22.4%
Quick ratio
4.21
Interest cover
7.88
ROIC
34.9%
Payout ratio
0.0%
FCF after stock pay
96.7M
Goodwill / assets
1.1%
Oper. margin low 5y
-125.6%
Tax rate
-77.0%
Stock pay / sales
6.1%
Shares out.
34.7M
Shares Y/Y
+15.1%
Book / share
15.86
Cash / share
14.72
Sales / share
20.95
Asset turnover
0.48
Inventory turns
4.96
Days sales out.
51
Sales 3Y CAGR
+86.4%
Sales 5Y CAGR
+84.5%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2018 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 605.5M +70.2% a year Net income 190.3M
FY2018 revenue 14.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-20-011409 FY2018 net income -23.8M · NetIncomeLoss, 0001564590-20-011409 14.7M FY2018 FY2019 revenue 25.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-21-012527 FY2019 net income -33.5M · NetIncomeLoss, 0001564590-21-012527 25.8M FY2019 FY2020 revenue 28.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-22-008045 FY2020 net income -28.7M · NetIncomeLoss, 0001564590-21-012527 28.4M FY2020 FY2021 revenue 31.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-22-008045 FY2021 net income -44.2M · NetIncomeLoss, 0000950170-24-021155 31.4M FY2021 FY2022 revenue 93.5M · Revenues, 0000950170-25-029104 FY2022 net income -36.2M · NetIncomeLoss, 0000950170-25-029104 93.5M FY2022 FY2023 revenue 241.6M · Revenues, 0001193125-26-067032 FY2023 net income -25.0M · NetIncomeLoss, 0001193125-26-067032 241.6M FY2023 FY2024 revenue 441.5M · Revenues, 0001193125-26-067032 FY2024 net income 35.5M · NetIncomeLoss, 0001193125-26-067032 441.5M FY2024 FY2025 revenue 605.5M · Revenues, 0001193125-26-067032 FY2025 net income 190.3M · NetIncomeLoss, 0001193125-26-067032 605.5M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2018 to FY2025 (7 years).

Growth per share, FY2018 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +22.6% a year FY2020 $4.21 to FY2025 $11.67, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $4.87$11.67$3.30
Dec 31, 2024 $1.01$6.49-$2.30
Dec 31, 2023 -$0.77$4.22-$5.07
Dec 31, 2022 -$1.23$6.34-$1.95
Dec 31, 2021 -$1.60$2.46-$1.17
Dec 31, 2020 -$1.16$4.21-$1.24
Dec 28, 2019 ---
Dec 29, 2018 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $637.8M
  • − All liabilities $595.3M
  • = Net current asset value $42.5M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $473.1M
  • − Goodwill $11.5M
  • − Other intangible assets $1.9M
  • = Tangible book value $459.6M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

TMDX against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+37.1%23rd of 155 · median +10.5%
Net margin
-4.1%15.3%
19.9%24th of 154 · median 6.8%
Return on equity
-5.2%18.5%
26.2%19th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
6.1%91st of 145 · median 10.0%
TMDX and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
TMDX TransMedics Group, Inc.$727.6M +37.1%58.6%19.9%26.2%6.1%-
RGEN Repligen Corp$805.6M +16.4%53.5%-1.5%-0.6%13.2%0.27
RARE Ultragenyx Pharmaceutical Inc.$730.0M +20.2%--71.8%--60.5%-
GKOS GLAUKOS Corp$690.3M +32.3%64.8%-24.6%-23.7%5.2%-
TARS Tarsus Pharmaceuticals, Inc.$682.2M +147%--102.9%-4.8%0.70
MIRM Mirum Pharmaceuticals, Inc.$670.8M +54.7%--134.8%--40.8%-
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $441.5M of sales to $35.5M of profit FY2024

  • Net product revenue $273.7M
  • Service Revenue $167.7M
  • Service Unrelated to OCS Transplant $4.4M
  • Unrelated to OCS Transplant $4.4M
Revenue to Gross profit: $262.1MRevenue to Cost of revenue: $179.5MGross profit to Operating profit: $37.5MGross profit to Operating expenses: $224.6MOperating profit to Net profit: $35.5MOperating profit to Tax & other: $2.0MOperating expenses to R&D: $56.0MOperating expenses to SG&A: $168.6M Revenue: $441.5M REVENUE $441.5M +83% Y/Y Gross profit: $262.1M · 59% margin GROSS PROFIT $262.1M 59% margin · +70% Y/Y Cost of revenue: $179.5M · 41% of revenue COST OF REVENUE $179.5M 41% of revenue Operating profit: $37.5M · 8% margin OPERATING PROFIT $37.5M 8% margin Operating expenses: $224.6M · 51% of revenue OPERATING EXPENSES $224.6M 51% of revenue Net profit: $35.5M · 8% margin NET PROFIT $35.5M 8% margin Tax & other: $2.0M · 0% of revenue TAX & OTHER $2.0M 0% of revenue R&D: $56.0M · 13% of revenue R&D $56.0M 13% of revenue SG&A: $168.6M · 38% of revenue SG&A $168.6M 38% of revenue

From $605.5M of sales to $190.3M of profit FY2025

  • Net product revenue $372.4M
  • Service Revenue $233.1M
  • Service Unrelated to OCS Transplant $4.1M
Revenue to Gross profit: $362.8MRevenue to Cost of revenue: $242.7MGross profit to Operating profit: $108.6MGross profit to Operating expenses: $254.2MOperating profit to Net profit: $108.6MOther income to Net profit: $81.7MOperating expenses to R&D: $69.1MOperating expenses to SG&A: $185.2M Revenue: $605.5M REVENUE $605.5M +37% Y/Y Gross profit: $362.8M · 60% margin GROSS PROFIT $362.8M 60% margin · +38% Y/Y Cost of revenue: $242.7M · 40% of revenue COST OF REVENUE $242.7M 40% of revenue Operating profit: $108.6M · 18% margin OPERATING PROFIT $108.6M 18% margin · +190% Y/Y Other income: $81.7M · 13% of revenue OTHER INCOME $81.7M 13% of revenue Operating expenses: $254.2M · 42% of revenue OPERATING EXPENSES $254.2M 42% of revenue Net profit: $190.3M · 31% margin NET PROFIT $190.3M 31% margin · +437% Y/Y R&D: $69.1M · 11% of revenue R&D $69.1M 11% of revenue SG&A: $185.2M · 31% of revenue SG&A $185.2M 31% of revenue

Where each $100 of sales went

FY2024
FY2025
  • Cost of revenue
  • R&D
  • Costs, tax, other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 40.2% FY2020: -27.7% net income ÷ equity
Net margin 31.4% FY2020: -101.4% profit per $ of sales: 190.3M ÷ 605.5M
Asset turnover 0.57× FY2020: 0.19× sales per $ of assets: 605.5M ÷ 1.1B
Leverage 2.26× FY2020: 1.46× assets per $ of equity: 1.1B ÷ 473.1M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    19.9% vs 6.8%
  • Gross margin up over 5 years
    58.7% → 59.9%
  • Return on equity above 15%
    26.2%
  • A profit in 2 of 8 years
Net margin, FY2018 to FY2025: -162.1% to 31.4%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 7.9× interest expense
  • Current assets cover current liabilities
    Current ratio 4.53
Debt / equity at each year end, FY2018 to FY2025: 0.62 to 0.31

Cash and shareholders

  • Free cash flow positive in 1 of 8 years
    $133.6M last year
  • Share count up over 5 years
    +64.1%
  • Cash from operations above net income
    $192.8M vs $190.3M
Free cash flow, FY2018 to FY2025: -26.4M to 133.6M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities, current part

Paid in advance $1.5M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · -54.7% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

TMDX's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 8. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue605.5M
FY2018: 14.7MFY2019: 25.8MFY2020: 28.4MFY2021: 31.4MFY2022: 93.5MFY2023: 241.6MFY2024: 441.5MFY2025: 605.5M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income190.3M
FY2018: -23.8MFY2019: -33.5MFY2020: -28.7MFY2021: -44.2MFY2022: -36.2MFY2023: -25.0MFY2024: 35.5MFY2025: 190.3M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow133.6M
FY2018: -26.4MFY2019: -32.5MFY2020: -30.7MFY2021: -32.4MFY2022: -57.7MFY2023: -164.9MFY2024: -80.9MFY2025: 133.6M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay96.7M
FY2018: -26.5MFY2019: -33.3MFY2020: -33.1MFY2021: -39.3MFY2022: -68.0MFY2023: -184.7MFY2024: -114.2MFY2025: 96.7M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)4.87
FY2018: -17.48FY2019: -2.36FY2020: -1.16FY2021: -1.60FY2022: -1.23FY2023: -0.77FY2024: 1.01FY2025: 4.87 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Dividend per share0.00
FY2018: -FY2019: 0.00FY2020: 0.00FY2021: 0.00FY2022: 0.00FY2023: 0.00FY2024: 0.00FY2025: 0.00 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares40.5M
FY2018: -FY2019: -FY2020: 24.7MFY2021: 27.6MFY2022: 29.6MFY2023: 32.5MFY2024: 35.2MFY2025: 40.5M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Net product revenue 372.4M61.5% +36.1%
Service Revenue 233.1M38.5% +39.0%
Service Unrelated to OCS Transplant 4.1M0.7% -6.8%

10-K 0001193125-26-067032, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue14.7M25.8M28.4M31.4M93.5M241.6M441.5M605.5M
Cost of revenue7.3M9.7M9.0M9.1M28.2M87.5M179.5M242.7M
Gross profit5.7M13.9M16.6M21.2M65.3M154.1M262.1M362.8M
R&D13.7M19.9M18.8M22.3M26.8M36.1M56.0M69.1M
SG&A12.3M23.6M24.2M38.3M69.9M119.6M168.6M185.2M
Operating income-20.2M-29.6M-26.4M-39.4M-31.4M-28.7M37.5M108.6M
Interest expense2.7M4.4M4.0M3.9M3.7M10.8M14.4M13.8M
Pretax income-23.7M-33.5M-28.7M-44.2M-36.2M-26.7M35.8M107.5M
Income tax000-66K-1.6M316K-82.8M
Net income-23.8M-33.5M-28.7M-44.2M-36.2M-25.0M35.5M190.3M
EPS (diluted)-17.48-2.36-1.16-1.60-1.23-0.771.014.87
Diluted shares--24.7M27.6M29.6M32.5M35.2M40.5M
Depreciation & amortization769K1.2M1.6M1.8M3.5M8.2M19.8M27.2M
EBITDA-19.5M-28.4M-24.8M-37.6M-28.0M-20.6M57.3M135.8M
Gross margin39.1%53.6%58.7%67.4%69.8%63.8%59.4%59.9%
Operating margin-138.1%-114.5%-93.0%-125.6%-33.6%-11.9%8.5%17.9%
Net margin-162.1%-129.8%-101.4%-140.9%-38.8%-10.4%8.0%31.4%
Revenue growth-+76.3%+9.7%+10.7%+198%+159%+82.7%+37.1%
EPS growth-------+382%

Balance sheet

From EDGAR

Cash flow

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-26.0M-32.3M-30.3M-28.9M-45.8M-13.0M48.8M192.8M
Capital spending418K165K455K3.5M11.9M151.8M129.7M59.3M
Free cash flow-26.4M-32.5M-30.7M-32.4M-57.7M-164.9M-80.9M133.6M
Stock-based pay (added back)144K854K2.4M6.9M10.3M19.8M33.2M36.9M
Free cash flow after stock pay-26.5M-33.3M-33.1M-39.3M-68.0M-184.7M-114.2M96.7M
Acquisitions-----14.9M--
Debt raised33.4M---58.5M---
Debt repaid9.1M---36.0M---
Investing cash flow12.3M-60.5M-41.6M29.3M54.5M-194.0M-129.3M-59.3M
Financing cash flow22.1M92.7M75.5M1.4M167.9M400.4M22.9M16.9M
Dividend per share-0.000.000.000.000.000.000.00

Stock-based pay and leases

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)144K854K2.4M6.9M10.3M19.8M33.2M36.9M
Stock-based pay / revenue1.0%3.3%8.5%21.9%11.0%8.2%7.5%6.1%
Operating lease cost---1.4M1.4M1.7M2.2M2.7M
Operating lease cash paid---1.9M1.9M2.2M2.9M3.4M
Right-of-use assets---5.8M5.1M6.5M6.5M5.2M
Operating lease liabilities---8.6M8.9M9.7M9.0M6.9M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TMDX/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.